Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.2K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

823
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
823
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.2K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

3.4K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action.

Journal of human hypertension·2007
Same author

Development of explicit criteria to measure adherence to hypertension guidelines.

Journal of human hypertension·2006
Same author

The paradigm has shifted to systolic blood pressure.

Journal of human hypertension·2004
Same author

Calcium antagonists in hypertension.

Blood pressure·2002
Same author

Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy.

American journal of hypertension·2002
Same author

Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease.

American heart journal·2001

Related Experiment Videos

Cough and ACE inhibitors.

S R Simon1, H R Black, M Moser

  • 1Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn.

Archives of Internal Medicine
|August 1, 1992
PubMed
Summary
This summary is machine-generated.

Angiotensin-converting enzyme (ACE) inhibitor antihypertensive therapy causes a significant cough side effect, affecting 25% in private practice and 13% in university settings. This incidence exceeds published data, necessitating clinical awareness to prevent misdiagnosis.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Pharmacy

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors are widely prescribed antihypertensive medications.
  • Cough is a known, albeit often underreported, side effect of ACE inhibitor therapy.
  • Variability in reported incidence suggests a need for further prevalence assessment.

Purpose of the Study:

  • To determine the actual prevalence of cough as a side effect of ACE inhibitor antihypertensive therapy.
  • To compare the incidence of ACE inhibitor-induced cough between private and university-based hypertension practices.
  • To highlight the discrepancy between observed and documented side effect rates.

Main Methods:

  • Retrospective chart review of 300 patients from a private practice.
  • Retrospective chart review of 200 patients from a university-based referral center for hypertension.
  • Analysis of patient records to identify and quantify ACE inhibitor-induced cough.

Main Results:

  • A 25% incidence of definite ACE inhibitor-induced cough was observed in the private practice setting.
  • In the university practice, 7% experienced definite cough, with an additional 6% reporting possible cough.
  • The observed incidence rates are substantially higher than those typically listed in the Physicians' Desk Reference.

Conclusions:

  • The prevalence of ACE inhibitor-induced cough is considerably higher than commonly reported.
  • Significant variability in incidence exists between different clinical practice settings.
  • Clinicians require heightened awareness of this side effect to prevent unnecessary diagnostic workups.